Physician profile
Ryan Garber
NPI 1811558554
$3,564.21
in general payments reported to CMS, 2019-2025
19 companies · $842 in 2025
The $842 reported for 2025 was more than what 88% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $501 · 2022: $599 · 2023: $985 · 2024: $637 · 2025: $842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,463.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $513.51 | 2022-2025 | Hydrus Microstent, Tryptyr, Rocklatan |
| Biotissue Holdings INC. | $426.98 | 2023-2025 | |
| Bausch & Lomb Americas INC. | $396.29 | 2023-2024 | Miebo, Xiidra, Xipere |
| Abbvie INC. | $311.47 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $281.69 | 2021-2025 | Cequa, Xelpros, Bromsite |
| Rxsight INC | $238.08 | 2023-2024 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Tarsus Pharmaceuticals, INC. | $222.19 | 2024-2025 | Xdemvy |
| Apellis Pharmaceuticals, INC. | $209.50 | 2023-2025 | Syfovre |
| Novartis Pharmaceuticals Corporation | $145.89 | 2022-2023 | |
| Sight Sciences, INC. | $143.05 | 2022 | |
| Kala Pharmaceuticals, INC. | $142.53 | 2021 | |
| Thea Pharma INC. | $118.42 | 2025 | Iyuzeh |
| Aerie Pharmaceuticals, INC. | $118.27 | 2021 | |
| Glaukos Corporation | $116.67 | 2021 | |
| Amgen INC. | $60.44 | 2024-2025 | Tepezza |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $43.73 | 2022-2023 | Tepezza |
| Dompe US, INC. | $31.10 | 2025 | Oxervate |
| Harrow Eye, LLC | $27.22 | 2025 | Vevye |
| Oyster Point Pharma, INC. | $17.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Garber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.